Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, will hold a board meeting on Thursday, November 12, 2026, to consider and approve the unaudited financial statements along with a limited review report for the half-year ended September 30, 2026, according to a regulatory filing with the BSE Limited.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved shifting the company's registered office from Office No. A -431, Balaji Bhavan, 4th Floor, Plot No 42A, Sector -11 CBD Belapur, Navi Mumbai, Maharashtra, 400614 to Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai, Maharashtra – 410210, effective October 15, 2026.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, will hold a board meeting on Tuesday, October 13, 2026, to consider and approve the shifting of the company's registered office address and the acquisition of immovable property through a Bank/Financial Institution auction.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its members approved the re-appointment of Ashish Narayan Sakalkar as Managing Director, and the appointment of M/s Panchal S K & Associates as Statutory Auditors, at a shareholder resolution passed on September 29, 2026. The company also announced increases in the remuneration of Saili Jayaram More, Whole-time Director and CEO, and Sachin Chandrakant Badakh, Non-Executive Director.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its members approved the re-appointment of Ashish Narayan Sakalkar as Managing Director, and the appointment of M/s Panchal S K & Associates as Statutory Auditors, at a shareholder resolution passed on September 29, 2026. The company also disclosed that remuneration increases were approved for Ashish Narayan Sakalkar, Saili Jayaram More, and Sachin Chandrakant Badakh.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved the allotment of 24,10,431 equity shares with a face value of Rs 10 each, issued at Rs 115 per share, including a premium of Rs 105. The company's paid-up equity share capital now stands at Rs 10,92,27,910, comprising 1,09,22,791 equity shares. The allotment was made to 15 investors, including Vijay Rathee, Vijaylaxmi Infra Projects Private Limited, and Swapneel Pradeep Rane, with Vijay Rathee receiving 13,17,391 shares.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved the allotment of 24,10,431 equity shares with a face value of Rs 10 each, issued at Rs 115 per share, including a premium of Rs 105. The company's paid-up equity share capital now stands at Rs 10,92,27,910, comprising 1,09,22,791 equity shares. The allotment was made to 15 investors, including Vijay Rathee, Vijaylaxmi Infra Projects Private Limited, and Swapneel Pradeep Rane, with Vijay Rathee receiving 13,17,391 shares.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors, both effective September 4, 2026, following a board meeting. The board also recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director and approved proposed increases in remuneration for Mr. Sakalkar, Mrs. Saili Jayaram More (Whole-time Director and CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), all subject to member approval.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors, both effective September 4, 2026, subject to shareholder approval. The board also recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director and approved increases in remuneration for Mr. Sakalkar, Mrs. Saili Jayaram More (Whole-time Director and CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), pending member approval.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors, both effective September 4, 2026, following a board meeting. The board also recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director and approved proposed increases in remuneration for Mr. Sakalkar, Mrs. Saili Jayaram More (Whole-time Director and CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), all subject to member approval.